SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX

Molecular Endocrinology

Volumn 22, Issue 9, 2008, Pages 2061-2075

  Holmstrom, Sam R ^a,c   Chupreta, Sergey ^a   So, Alex Yick Lun ^b   Iñiguez Lluhí, Jorge A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; GLUCOCORTICOID RECEPTOR; SUMO PROTEIN;

ARTICLE; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SUMOYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID MOTIFS; ANIMALS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; DNA; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, QUATERNARY; RATS; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; RNA, SMALL INTERFERING; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 50649103009     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0581     Document Type: Article

References (82)

1. Iñiguez-Lluhí JA, Pearce D 2000 A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol Cell Biol 20:6040-6050
2. Tian S, Poukka H, Palvimo JJ, Janne OA 2002 Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem J 367:907-911
3. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2000 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150
4. Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB 2002 The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem 277:33950-33956
5. Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama S, Nakayama KI, Yamamoto H, Kikuchi A, Morohashi K 2004 Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9. Mol Endocrinol 18:2451-2462
6. Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, Ingraham HA 2005 The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol 25:1879-1890
7. Vu EH, Kraus RJ, Mertz JE 2007 Phosphorylation-dependent sumoylation of estrogen-related receptor α1. Biochemistry 46:9795-9804
8. Tremblay AM, Wilson BJ, Yang XJ, Giguere V 2008 Phosphorylation-dependent sumoylation regulates estrogen-related receptor-α and -γ transcriptional activity through a synergy control motif. Mol Endocrinol 22:570-584
9. Subramanian L, Benson MD, Iñiguez-Lluhí JA 2003 A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein α inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J Biol Chem 278:9134-9141
10. Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE 2005 Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem 280:146-155
11. Chupreta S, Brevig H, Bai L, Merchant JL, Iniguez-Lluhi JA 2007 Sumoylation-dependent control of homotypic and heterotypic synergy by the Kruppel-type zinc finger protein ZBP-89. J Biol Chem 282:36155-36166
12. Murakami H, Arnheiter H 2005 Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res 18:265-277
13. Rodriguez MS, Dargemont C, Hay RT 2001 SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 276:12654-12659
14. Chupreta S, Holmstrom S, Subramanian L, Iñiguez-Lluhí JA 2005 A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties. Mol Cell Biol 25:4272-4282
15. Holmstrom S, Van Antwerp ME, Iñiguez-Lluhí JA 2003 Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy. Proc Natl Acad Sci USA 100:15758-15763
16. Bies J, Markus J, Wolff L 2002 Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem 277:8999-9009
17. Callewaert L, Verrijdt G, Haelens A, Claessens F 2004 Differential effect of small ubiquitin-like modifier (SUMO)-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. Mol Endocrinol 18:1438-1449
18. Chun TH, Itoh H, Subramanian L, Iñiguez-Lluhí JA, Nakao K 2003 Modification of GATA-2 transcriptional activity in endothelial cells by the SUMO E3 ligase PIASy. Circ Res 92:1201-1208
19. Hirano Y, Murata S, Tanaka K, Shimizu M, Sato R 2003 Sterol regulatory element-binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway. J Biol Chem 278:16809-16819
20. Ross S, Best JL, Zon LI, Gill G 2002 SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol Cell 10:831-842
21. Sapetschnig A, Rischitor G, Braun H, Doll A, Schergaut M, Melchior F, Suske G 2002 Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J 21:5206-5215
22. Tallec LP, Kirsh O, Lecomte MC, Viengchareun S, Zennaro MC, Dejean A, Lombes M 2003 Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 17:2529-2542
23. Yang SH, Jaffray E, Hay RT, Sharrocks AD 2003 Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 12:63-74
24. Zheng G, Yang YC 2004 ZNF76, a novel transcriptional repressor targeting TATA-binding protein, is modulated by sumoylation. J Biol Chem 279:42410-42421
25. Saitoh H, Hinchey J 2000 Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275:6252-6258
26. Su HL, Li SS 2002 Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296:65-73
27. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D 2004 A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type 1 diabetes mellitus. J Biol Chem 279:27233-27238
28. Johnson ES 2004 Protein modification by SUMO. Annu Rev Biochem 73:355-382
29. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM 2005 A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 337:517-520
30. Sampson DA, Wang M, Matunis MJ 2001 The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem 276:21664-21669
31. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R 2001 PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15:3088-3103
32. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F 2002 The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108:109-120
33. Yeh ET, Gong L, Kamitani T 2000 Ubiquitin-like proteins: new wines in new bottles. Gene 248:1-14
34. Rosendorff A, Sakakibara S, Lu S, Kieff E, Xuan Y, DiBacco A, Shi Y, Shi Y, Gill G 2006 NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci USA 103:5308-5313
35. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI, Hung CC, Suen CS, Hwang MJ, Chang KS, Maul GG, Shih HM 2006 Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24:341-354
36. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y 2004 Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA 101:14373-14378
37. Reverter D, Lima CD 2005 Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435:687-692
38. Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, Emili A, Hochstrasser M 2005 Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280:4102-4110
39. Hecker C-M, Rabiller M, Haglund K, Bayer P, Dikic I 2006 Specification of SUMO1- and SUMO2-interacting Motifs. J Biol Chem 281:16117-16127
40. Stielow B, Sapetschnig A, Kruger I, Kunert N, Brehm A, Boutros M, Suske G 2008 Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol Cell 29:742-754
41. Yang SH, Sharrocks AD 2004 SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 13:611-617
42. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB 1991 Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497-505
43. Liu W, Wang J, Yu G, Pearce D 1996 Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Mol Endocrinol 10:1399-1406
44. Schmid W, Strähle U, Schütz G, Schmitt J, Stunnenberg H 1989 Glucocorticoid receptor binds cooperatively to adjacent recognition sites. EMBO J 8:2257-2263
45. Wright AP, Gustafsson JA 1991 Mechanism of synergistic transcriptional transactivation by the human glucocorticoid receptor. Proc Natl Acad Sci USA 88:8283-8287
46. Strähle U, Schmid W, Schütz G 1988 Synergistic action of the glucocorticoid receptor with transcription factors. EMBO J 7:3389-3395
47. Adams M, Meijer OC, Wang J, Bhargava A, Pearce D 2003 Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol 17:2583-2592
48. Schena M, Freedman LP, Yamamoto KR 1989 Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities. Genes Dev 3:1590-1601
49. Godowski PJ, Rusconi S, Miesfeld R, Yamamoto KR 1987 Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement. Nature 325:365-368
50. Dahlman-Wright K, Wright APH, Gustafsson J 1992 Determinants of high-affinity DNA binding by the glucocorticoid receptor: evaluation of receptor domains outside the DNA-binding domain. Biochemistry 31:9040-9044
51. Li Q, Johnston SA 2001 Are all DNA binding and transcription regulation by an activator physiologically relevant? Mol Cell Biol 21:2467-2474
52. Kang T, Martins T, Sadowski I 1993 Wild type GAL4 binds cooperatively to the GAL1-10 UASG in vitro. J Biol Chem 268:9629-9635
53. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR 2007 Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3:e94
54. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M 2003 Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab 88:277-284
55. Magee JA, Chang LW, Stormo GD, Milbrandt J 2006 Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147:590-598
56. Hubler TR, Scammell JG 2004 Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 9:243-252
57. Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD 2002 Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108:345-356
58. Hietakangas V, Anckar J, Blomster HA, Fujimoto M, Palvimo JJ, Nakai A, Sistonen L 2006 PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci USA 103:45-50
59. Daniel AR, Faivre EJ, Lange CA 2007 Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 21:2890-2906
60. Chalepakis G, Schauer M, Cao X, Beato M 1991 Efficient binding of glucocorticoid receptor to its responsive element requires a dimer and DNA flanking sequences. DNA Cell Biol 9:355-368
61. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G 1998 DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531-541
62. Wintermantel TM, Berger S, Greiner EF, Schutz G 2004 Genetic dissection of corticosteroid receptor function in mice. Horm Metab Res 36:387-391
63. Chen WY, Lee WC, Hsu NC, Huang F, Chung BC 2004 SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1). J Biol Chem 279:38730-38735
64. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105
65. Brandt ME, Vickery LE 1997 Cooperativity and dimerization of recombinant human estrogen receptor hormone-binding domain. J Biol Chem 272:4843-4849
66. Lees JA, Fawell SE, White R, Parker MG 1990 A 22-amino-acid peptide restores DNA-binding activity to dimerization-defective mutants of the estrogen receptor. Mol Cell Biol 10:5529-5531
67. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
68. Perlmann T, Umesono K, Rangarajan PN, Forman BM, Evans RM 1996 Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. Mol Endocrinol 10:958-966
69. Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W, Claessens F 2000 Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 275:12298-12305
70. Rees-Unwin KS, Craven RA, Davenport E, Hanrahan S, Totty NF, Dring AM, Banks RE, J Morgan G, Davies FE 2007 Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br J Haematol 139:559-567
71. Ryu SW, Chae SK, Kim E 2000 Interaction of Daxx, a Fas binding protein, with sentrin and Ubc9. Biochem Biophys Res Commun 279:6-10
72. Jang MS, Ryu SW, Kim E 2002 Modification of Daxx by small ubiquitin-related modifier-1. Biochem Biophys Res Commun 295:495-500
73. Chang CC, Lin DY, Fang HI, Chen RH, Shih HM 2005 Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J Biol Chem 280:10164-10173
74. Shiio Y, Eisenman RN 2003 Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 100:13225-13230
75. Nathan D, Ingvarsdottir K, Sterner DE, Bylebyl GR, Dokmanovic M, Dorsey JA, Whelan KA, Krsmanovic M, Lane WS, Meluh PB, Johnson ES, Berger SL 2006 Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev 20:966-976
76. Kotaja N, Karvonen U, Janne OA, Palvimo JJ 2002 The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283-30288
77. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND, Hay RT 2003 P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11:1043-1054
78. Nakagawa K, Kuzumaki N 2005 Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification. Genes Cells 10:835-850
79. Wu H, Sun L, Zhang Y, Chen Y, Shi B, Li R, Wang Y, Liang J, Fan D, Wu G, Wang D, Li S, Shang Y 2006 Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 281:21848-21856
80. Boyer-Guittaut M, Birsoy K, Potel C, Elliott G, Jaffray E, Desterro JM, Hay RT, Oelgeschlager T 2005 SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5. J Biol Chem 280:9937-9945
81. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, Turner DL 2006 Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 34:e53
82. Gametchu B, Harrison RW 1984 Characterization of a monoclonal antibody to the rat liver glucocorticoid receptor. Endocrinology 114:274-279